MetaVia completes dose titration in Phase 1 Part 3 of DA-1726 obesity trial; topline data on track for Q4 2026

MetaVia Inc.

All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.
Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks, plus reductions in waist circumference and glycemic measures.
Part 3 enrolls ~40 obese subjects randomized 4:1 active:placebo across two 16-week titration cohorts.
Topline data from Part 3 remains on track for release in Q4 2026.
CEO cites favorable tolerability and efficient titration as potential competitive advantage over marketed obesity therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.